Lannett (LCI) –
-
US Energy Department Set To Unveil Final Rules On Tuesday That Will Soften Proposal To Slash Electric Vehicle Mileage Ratings To Meet Fuel Economy Rules - Reuters
-
Lannett Company, Inc. Enters Into Restructuring Support Agreement
-
Form 8-K LANNETT CO INC For: Apr 19
-
NYSE to Immediately Suspend Trading in Lannett (LCI), Commences Delisting
-
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
-
NYSE to Suspend Trading Immediately in Lannett Company, Inc. (LCI) and Commence Delisting Proceedings
-
Lannett (LCI) Halted, News Pending
-
Form 8-K LANNETT CO INC For: Apr 11
-
Form 8-K LANNETT CO INC For: Apr 04
-
Lannett (LCI) Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product
-
LANNETT SHARES UPDATE
-
Form SC 13G/A LANNETT CO INC Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
-
Form 8-K LANNETT CO INC For: Feb 06
-
Form 10-Q LANNETT CO INC For: Dec 31
-
Form 8-K LANNETT CO INC For: Feb 01
-
Lannett (LCI) Tops Q2 EPS by 7c
-
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE
-
Form 8-K LANNETT CO INC For: Jan 25
-
Lannett (LCI) Announces 1:4 Reverse Stock Split
-
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT
-
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1
-
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
-
Form 8-K LANNETT CO INC For: Dec 15
-
Form DEF 14A LANNETT CO INC For: Jan 25
-
Form 4 LANNETT CO INC For: Nov 17 Filed by: Chapman John C
-
Form 4 LANNETT CO INC For: Nov 10 Filed by: LEPORE PATRICK G
-
Form 4 LANNETT CO INC For: Nov 10 Filed by: Crew Timothy C
-
Form 8-K LANNETT CO INC For: Nov 07
-
Form PRE 14A LANNETT CO INC For: Nov 10
-
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM
-
Form 10-Q LANNETT CO INC For: Sep 30
-
Form 8-K LANNETT CO INC For: Nov 02
-
LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE
-
LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2
-
Lannett (LCI) Granted FDA Approval to Manufacture Numbrino at Seymour Plant
-
LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT
-
Lannett (LCI) Sells Several Discontinued Drugs for $3M
-
LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS
-
Form 4 LANNETT CO INC For: Sep 14 Filed by: Rewolinski Melissa
-
Form 4 LANNETT CO INC For: Sep 07 Filed by: KOZLOWSKI JOHN
-
Form 4 LANNETT CO INC For: Sep 07 Filed by: Abt John
-
LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE
-
Form 10-K LANNETT CO INC For: Jun 30
-
Form 8-K LANNETT CO INC For: Aug 24
-
Lannett (LCI) Tops Q2 EPS by 2c
-
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
-
LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24
-
Form 4 LANNETT CO INC For: Jul 29 Filed by: Cavanaugh Maureen
-
Form 4 LANNETT CO INC For: Jul 29 Filed by: Abt John
-
Form 4 LANNETT CO INC For: Jul 29 Filed by: Israel Samuel H
Back to LCI Stock Lookup